Bioxtreme
Bioxtreme develops FDA-cleared robotic rehabilitation devices (Plaxtreme and Dextreme) using proprietary Error Augmentation technology to accelerate upper limb motor recovery in post-stroke patients, selling through direct enterprise sales to hospitals and rehabilitation centers across North America and Europe.
- Company typePrivate
- Founded2010
- HeadquartersPetah Tiqva, Israel
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bioxtreme does
Bioxtreme is a medical device company that develops and commercializes robotic rehabilitation systems for upper limb motor recovery, primarily targeting post-stroke patients. The company sells two FDA-cleared, CE-marked, and ISO 13485-certified devices: Plaxtreme, a precision robotic system for hand and finger rehabilitation (grasp, release, supination/pronation), and Dextreme, an advanced robotic system for shoulder, elbow, and arm range-of-motion training. Both products are powered by the company's proprietary Error Augmentation technology, a patented approach that amplifies movement errors during therapy to trigger enhanced neural plasticity and accelerate motor learning, in contrast to conventional rehabilitation that focuses on error correction.
The technology platform is rooted in 10+ years of Northwestern University research and has been validated through clinical trials across North America and Europe, with measurement claims including up to 40% improvement in upper limb function over five years, 2X improvement in Fugl-Meyer scores, 4X improvement in Modified Ashworth Scale (MAS) versus standard robotic therapy, and clinically significant motor improvements in two weeks. Bioxtreme generates revenue through direct enterprise sales of its robotic medical devices to hospitals, rehabilitation centers, and healthcare systems, supplemented by professional services including device calibration, training, and ongoing clinical support. Pricing is quote-based and not publicly disclosed, with multi-year contracts negotiated through a consultative sales process anchored on clinical evidence presentation and device demonstrations. The company is privately held as Bioxtreme Ltd., with no disclosed funding rounds, headcount, or revenue figures.
Bioxtreme firmographics
Firmographics- Name
- Bioxtreme
- Legal name
- Bioxtreme Ltd.
- Website
- https://bio-xtreme.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Bioxtreme develops FDA-cleared robotic rehabilitation devices (Plaxtreme and Dextreme) using proprietary Error Augmentation technology to accelerate upper limb motor recovery in post-stroke patients, selling through direct enterprise sales to hospitals and rehabilitation centers across North America and Europe.
- Ownership category
- akta.pro rank
Bioxtreme industry classification
Industry- Product category
- Rehabilitation Robotics
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Healthcare & Assistive Robotics (HDAAAIAC)
- akta.pro secondary industries
- Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG), Hand & Upper Extremity Therapy (OT/CHT) (HSADAIAH), Prosthetics/Orthotics Rehab & Amputee Rehabilitation (HSADAIAN)
Keywords
Where Bioxtreme is headquartered
LocationHeadquarters
- HQ city
- Petah Tiqva
- HQ country
- Israel
- HQ region
- Middle East
Markets served
Bioxtreme business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- Medical Device Sales: Sale of FDA-cleared rehabilitation robotic devices (Plaxtreme and Dextreme) to healthcare facilities, rehabilitation centers, and hospitals. Hardware-centric model with potential for ongoing maintenance and support services.
- Clinical Services and Support: Professional services including device calibration, training, and ongoing clinical support for healthcare facilities implementing Bioxtreme technology.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise pricing based on facility requirements |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Bioxtreme product offering
Product offeringCore offering
Bioxtreme manufactures and sells FDA-cleared robotic rehabilitation medical devices (Plaxtreme for hand/finger therapy and Dextreme for upper extremity therapy) that use its proprietary Error Augmentation technology to amplify movement errors during therapy sessions, accelerating neural plasticity and motor recovery in post-stroke and neurological patients. The offering is sold to healthcare facilities, rehabilitation centers, and hospitals, with supporting clinical services including device calibration, training, and ongoing clinical support.
Product overview
Bioxtreme offers a portfolio of two rehabilitation robotics products both powered by its proprietary Error Augmentation technology. Plaxtreme focuses on hand and finger rehabilitation (grasp, release, supination/pronation), while Dextreme™ addresses shoulder, elbow, and arm rehabilitation. Both products are FDA-cleared robotic medical devices designed for upper extremity motor recovery in individuals post-stroke.
Differentiator
Problem solved
Functional benefit
Brands
- Plaxtreme: Precision robotic therapy device for hands and fingers providing functional grasp, release, and rotational control through Error Augmentation technology. Features AI-driven personalized therapy and adjustable protocols.
- Dextreme™
Products and services
- Plaxtreme Plaxtreme is an FDA-cleared precision robotic hand and finger therapy device that delivers grasp, release, supination, and pronation training using Bioxtreme's proprietary Error Augmentation technology. It is designed for healthcare facilities and rehabilitation centers treating post-stroke and neurological patients needing fine motor skill and dexterity restoration, offering AI-driven personalized therapy protocols, easy set-up/calibration, task-based therapy, and adjustable protocols.
- Dextreme™ Dextreme™ is an FDA-cleared advanced robotic rehabilitation device for shoulders, elbows, and arms, providing full arm range of motion training with customizable therapy protocols and clinically validated outcomes for post-stroke motor recovery. It is intended for hospitals, rehabilitation centers, and healthcare systems offering upper extremity rehabilitation programs, featuring real-time data tracking, AI-driven personalized therapy, and clinically validated results.
- Clinical Services and Support Professional services offering device calibration, training, and ongoing clinical support to healthcare facilities and rehabilitation centers implementing Bioxtreme's Plaxtreme and Dextreme devices. Targeted at hospitals and rehabilitation centers adopting the technology into clinical workflows.
Quantifiable outcome
- Up to 40% improvement in upper limb function in 5 years
- +6 more outcomes
Companies that use Bioxtreme
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Bioxtreme technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
Bioxtreme partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and major.
- Northwestern UniversitycoreFoundational research partner for Bioxtreme's Error Augmentation technology. Over 10 years of research collaboration from Northwestern University validating the proprietary approach to neurorehabilitation through error amplification. The technology is built on groundbreaking research from this institution.
- Brooks Rehabilitation CentermajorPublished white paper on Dextreme™ as a Novel Robotic Device for Upper Extremity Rehabilitation. Clinical trial site validating the effectiveness of Bioxtreme's Error Augmentation technology in post-stroke rehabilitation.
- Reuth Rehabilitation HospitalmajorClinical partner providing feedback on Dextreme™ device capabilities. Therapist testimonial confirms ability to control amount of help given to patients according to their individual needs with visible improvement in arm functionality.
- Villa Beretta Rehabilitation Centre, Valduce HospitalmajorClinical validation partner with published white paper on Dextreme™. Features testimonial from Director of Physical Medicine and Rehabilitation Dr. Franco Molteni praising the precision Error Augmentation technology as excellent training path.
Scale indicators6 records
Recent moves5 records
Expansion highlights4 records
Bioxtreme competitors and assessment
Company assessmentDirect peers
- Hocoma (DIH): Hocoma, now part of DIH, makes the Armeo line of upper-extremity robotic rehabilitation devices (ArmeoPower, ArmeoSpring). It is the most established direct competitor in robotic upper-limb rehab and competes head-to-head with Bioxtreme's Dextreme and Plaxtreme for hospital and rehabilitation-center accounts.
- Saebo: Saebo specializes in upper-extremity rehabilitation products for stroke survivors, including the SaeboGlove, SaeboStretch, and SaeboMAS. While its product mix is more orthotic/functional-electrical-stimulation oriented, it competes with Bioxtreme for the same therapist prescribing decisions and post-stroke upper-limb patient pathways.
- Fourier Intelligence: Fourier Intelligence offers the ArmMotus line of upper-limb rehabilitation robotics (EMU, M2 Pro) targeting stroke and neurological rehab. Its product positioning and target buyer (hospital rehabilitation departments) overlap significantly with Bioxtreme.
- Bionik Laboratories: Bionik Laboratories produced the InMotion ARM robotic system for upper-extremity rehabilitation post-stroke, directly competing with Dextreme. It targets the same hospital, rehabilitation center, and clinical research customers.
- Tyromotion: Tyromotion is a European (Austria-based) manufacturer of upper-extremity rehabilitation robotics including Amadeo (hand/fingers), Diego, and Pablo. Its product portfolio directly overlaps with Bioxtreme's hand and arm devices, serving the same clinical use cases in stroke and neurological rehabilitation.
Broad incumbents
- ReWalk Robotics: ReWalk Robotics develops wearable robotic exoskeletons for individuals with spinal cord injury and stroke. It serves a similar clinical rehabilitation buyer base but is focused on gait and mobility rather than upper-extremity motor recovery.
- Ekso Bionics: Ekso Bionics is a publicly traded rehabilitation robotics company best known for the EksoNR exoskeleton for gait rehabilitation. It operates in the same hospital/clinic robotics category but focuses on lower-extremity and gait rather than Bioxtreme's upper-limb niche.
Emerging players
- Kinova Robotics: Kinova is a Canadian-based manufacturer of robotic arms and assistive robotic platforms with applications in rehabilitation and research. It overlaps with Bioxtreme on the use of advanced robotics for motor recovery in clinical and research settings.
- ArmDynamics: ArmDynamics operates rehabilitation clinics and develops protocols and tools specifically for upper-extremity prosthetic and orthotic rehabilitation. It represents an emerging clinical channel and therapy approach that intersects with Bioxtreme's upper-limb recovery focus.
Regional players
- Motorika Medical: Motorika (Israel) produces the ReoGo and ReoAmbulator robotic rehabilitation systems for upper and lower extremity therapy. Its product focus on upper-limb motor recovery post-stroke directly mirrors Bioxtreme's clinical application, though its commercial reach has historically been more regional.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Bioxtreme social profiles
Digital presenceBioxtreme compliance and trust
Trust signalCompliance4 records
Bioxtreme financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bioxtreme leadership team
Management profileNumber of profiles
Bioxtreme funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bioxtreme M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bioxtreme
What does Bioxtreme do?
Bioxtreme manufactures and sells FDA-cleared robotic rehabilitation medical devices (Plaxtreme for hand/finger therapy and Dextreme for upper extremity therapy) that use its proprietary Error Augmentation technology to amplify movement errors during therapy sessions, accelerating neural plasticity and motor recovery in post-stroke and neurological patients. The offering is sold to healthcare facilities, rehabilitation centers, and hospitals, with supporting clinical services including device calibration, training, and ongoing clinical support.
Is Bioxtreme a public or private company?
Bioxtreme is a private company. It is classified as unknown and is currently operating.
When was Bioxtreme founded?
Bioxtreme was founded in 2010. It employs 1 to 10 people.
Where is Bioxtreme based?
Bioxtreme is headquartered in Petah Tiqva, Israel, in the Middle East region.
How does Bioxtreme make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are clinical Services and Support.
Who are Bioxtreme's main competitors?
Direct peers on record are Hocoma (DIH), Saebo, Fourier Intelligence, Bionik Laboratories and Tyromotion. Broad incumbents are ReWalk Robotics and Ekso Bionics. Emerging players are Kinova Robotics and ArmDynamics. Motorika Medical is listed as a regional player.
Does Bioxtreme have an API?
No public API is recorded for Bioxtreme.
What industry is Bioxtreme in?
Bioxtreme's product category is Rehabilitation Robotics. Its primary akta.pro industry code is HDAAAIAC, Healthcare & Assistive Robotics, with a secondary code of HLAHAMAG, Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices). Its NAICS code is 334510 and its SIC code is 3845.